File #: 17-1822    Version: 1 Name: City of Newark v Opioid Manufacturers
Type: Resolution Status: Adopted
File created: 10/16/2017 In control: Law
On agenda: 11/8/2017 Final action: 11/8/2017
Title: Dept/ Agency: Law Action: (X) Ratifying (X) Authorizing ( ) Amending Type of Service: Professional Services Contract Purpose: Affirmative Litigation Legal Services Entity's Name/Addresses: 1. D'Arcy Johnson Day, P.C., 3120 Fire Road, Suite 100, Egg Harbor Township, New Jersey 08234 2. Motley Rice, LLC., 401 9th Street, N.W., Suite 1001, Washington, D.C. 20004 3. Law Offices of Eric Pennington, P.C., 1 Gateway Center, Suite 105, Newark, New Jersey 07102 Contract Amount: Contingency Fee Funding Source: Contract Period: September 28, 2017 through September 27, 2018 Contract Basis: ( ) Bid ( ) State Vendor (X) Prof. Ser. ( ) EUS ( ) Fair & Open (X) No Reportable Contributions ( ) RFP ( ) RFQ ( ) Private Sale ( ) Grant ( ) Sub-recipient ( ) n/a Additional Information: Authorizing the City to retain the legal services of two (2) law firms to help it affirmatively address the opioid crisis by investigating pharmaceutical companies...
Sponsors: Council of the Whole
Title
Dept/ Agency: Law
Action: (X) Ratifying (X) Authorizing ( ) Amending
Type of Service: Professional Services Contract
Purpose: Affirmative Litigation Legal Services
Entity's Name/Addresses:
1. D'Arcy Johnson Day, P.C., 3120 Fire Road, Suite 100, Egg Harbor Township, New Jersey 08234
2. Motley Rice, LLC., 401 9th Street, N.W., Suite 1001, Washington, D.C. 20004
3. Law Offices of Eric Pennington, P.C., 1 Gateway Center, Suite 105, Newark, New Jersey 07102
Contract Amount: Contingency Fee
Funding Source:
Contract Period: September 28, 2017 through September 27, 2018
Contract Basis: ( ) Bid ( ) State Vendor (X) Prof. Ser. ( ) EUS
( ) Fair & Open (X) No Reportable Contributions ( ) RFP ( ) RFQ
( ) Private Sale ( ) Grant ( ) Sub-recipient ( ) n/a
Additional Information:
Authorizing the City to retain the legal services of two (2) law firms to help it affirmatively address the opioid crisis by investigating pharmaceutical companies and seeking to hold them accountable for their actions and misconduct.

body

WHEREAS, the misuse and abuse of opioid pain relievers is a major problem in the United States; and

WHEREAS, the Governor of New Jersey recently announced that he is prepared to spend $200 million to address the opioid crisis; and

WHEREAS, certain pharmaceutical companies manufacture, market, and sell prescription opioid pain medications, under a variety of brand-name drugs including, but not limited to, OxyContin, Butrans, Hysingla ER, Actiq, Fentora, Opana/Opana ER, Percodan, Percocet, Zydone and Duragesic; and

WHEREAS, medical studies have shown that prescription opioids are narcotics because they are derived from and possess properties similar to opium and heroin, which are regulated as controlled substances; and

WHEREAS, although opioids can lessen the perception of pain, they also can create an addictive, euphoric high to the user....

Click here for full text